Skip to main content

Travere Therapeutics

Travere Therapeutics Inc is an American biopharmaceutical company focused on identifying, developing, and commercializing therapies for rare kidney and metabolic diseases. The company commercializes Filspari (sparsentan), a first-in-class dual endothelin and angiotensin A receptor antagonist approved for reducing proteinuria in primary IgA nephropathy, alongside marketing Chenodal and Thiola for rare metabolic disorders. Main revenue drivers derive from commercial sales of Filspari, Chenodal, and Thiola specialty prescription pharmaceuticals directly to specialty pharmacies and healthcare providers. Travere Therapeutics serves nephrologists, endocrinologists, rare disease specialists, hospital centers, and patients with rare kidney conditions across North America and Europe. The company holds an innovative market position in rare nephrology and metabolic disease therapeutics. Headquartered in San Diego, California, Travere Therapeutics Inc is listed on the Nasdaq Stock Market.

6 of the funds FundTelligence covers report a position in Travere Therapeutics.

Legal name
Travere Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
6

Funds holding Travere Therapeutics

Loading...